Mr. Speaker, first, our heart goes out to families that have family members struggling with illness. It is truly heartbreaking.
We know the importance of patient access to new therapies for serious or life-threatening conditions. To date, the manufacturer of Trikafta has not submitted an application to market this product in Canada. It is the manufacturer's decision to apply to market its product in Canada. For serious or life-threatening conditions, such as cystic fibrosis, physicians may request access to the drug through the special access program.
To help Canadians get better access to effective treatments, we are working with provinces, territories and other partners to develop a national strategy for high-cost drugs for rare diseases.